The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study

Matthew E. Nielsen, Eric Edison, John McGrath, Nkwam Nkwam, Kenneth MacKenzie, Jonathan olivier, Matthew Jefferies, Tara Burnhope, Taha Uçar, Arjun K. Nambiar, Asim Lal, Beatrice Lillaz , Mark Assmus , Alison Downey , Naomi Chuchu , Eleanor Zimmermann, Yemisi Takwoingi, Juan Gómez Rivas, Sacha Moore, Chuanyu GaoGraeme MacLennan, Giancarlo Marra , Matteo Boltri , Holly Clarke, Francesco Claps, George Tanasescu, Kathryn Gillams , Miles Mannas, Veeru Kasivisvanathan, Kevin M. Gallagher, Marta Antón-Juanilla , David Lau, Nicholas Boxall, John O'Rourke, Matthew Crockett, Taeweon Lee , Taimur T. Shah, Sinan Khadhouri*, The IDENTIFY Study Group

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer (UTUC) and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. This was an international multicentre prospective observational study. We included patients aged 16 and over, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex and smoking. We used a multivariable mixed effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals and countries. Of the 11,059 patients assessed for eligibility, 10,896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n=2257) was 28.2% (95% CI 22.3-34.1), bladder cancer (n=1951) 24.7% (19.1-30.2), UTUC (n=128) 1.14% (0.77-1.52), renal cancer (n=107) 1.05% (0.80-1.29) and prostate cancer (n=124) 1.75% (1.32-2.18). Odds ratios for patient risk markers in the model for all cancers were: Age 1.04 (95% CI 1.03-1.05) p
Original languageEnglish
JournalBJU International
DOIs
Publication statusAccepted/In press - 6 May 2021

Fingerprint Dive into the research topics of 'The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study'. Together they form a unique fingerprint.

Cite this